Brief: Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
26/03/2025 20:07
March 26 (Reuters) - Savara Inc SVRA.O: SAVARA COMPLETES SUBMISSION OF THE BIOLOGICS LICENSE APPLICATION (BLA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR MOLBREEVI* AS A TREATMENT FOR AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) SAVARA INC - TO SUBMIT MOLBREEVI MAA IN EUROPE BY END OF 2025 SAVARA INC: COMMERCIAL PREPARATIONS ARE ON-TRACK TO SUPPORT A POTENTIAL LAUNCH IN EARLY 2026 Source text: ID:nBw6ZdRW0a Further company coverage: SVRA.O ((Reuters.Briefs@thomsonreuters.com;))